Login to Your Account


Late or just in time – a U.S. big biotech arrives, ready to innovate

By Shannon Ellis
Staff Writer

Wednesday, December 18, 2013

SHANGHAI – Amgen Inc. entered China in 2012, more than a decade after most other global players in the industry. While some may think the big biotech is a late comer, company execs say the time is just right to develop innovative drugs in a country where most drug makers focus on generics.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription